Trademark: 79330615
Word
CT CELLENGENE CELL AND GENE THERAPY
Status Date
Thursday, May 2, 2024
Filing Date
Friday, November 19, 2021
Abandoned Date
Monday, April 22, 2024
5 Pharmaceutical preparations for treating diabetes; pharmaceutical preparations for immunity adjustment; pharmaceutical preparations for regulating the immune system; pharmaceutical preparations for the treatment of cells; pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; biopharmaceuticals for the treatment of cancer; biological preparations for the treatment of cancer; pharmaceutical preparations for the treatment of cancer; biological preparations for medical purposes, namely, biological preparations for the treatment of cancer; stem cells for medical purposes; antidiabetic preparations; anti-diabetic pharmaceuticals; anti-cancer preparations
44 Medical services in the field of diabetes; medical services relating to the removal, treatment and processing of human blood, umbilical cord blood, human cells, stem cells and bone marrow; health care services for treating cancer; medical services relating to the removal, treatment and processing of human cells; medical analysis relating to clinical data, namely, medical analysis services for diagnostic and treatment purposes provided by medical laboratories
42 Development of cell therapy products, namely, research and development and consultation related thereto in the field of cell engineering technology; scientific research for medical purposes in the area of cancerous diseases; research services relating to pharmaceuticals, namely, stem cell research services; stem cell research services
The mark consists of the wording "CT CELLENGENE CELL AND GENE THERAPY". The letter "C" in "CT" is red; the letter "T" is yellow. The letter "C" in "CELLENGENE" is red; the rest of the letters are black. The wording "CELL AND GENE THERAPY" is in black.
The color of the background is white; also, the letters 'C' are colored in red and the letter 'T' is colored in yellow; the remaining letters are all black.
The color(s) red, yellow, and black is/are claimed as a feature of the mark.
"CELL AND GENE THERAPY"
Sep 14, 2022
Non-Final Action (Ib Refusal) Prepared For Review
Jan 6, 2022
Sn Assigned For Sect 66a Appl From Ib
Jan 7, 2022
New Application Office Supplied Data Entered
Jan 11, 2022
Application Filing Receipt Mailed
Aug 31, 2022
Assigned To Examiner
Sep 13, 2022
Non-Final Action Written
Nov 7, 2022
Refusal Processed By Mpu
Nov 7, 2022
Non-Final Action Mailed - Refusal Sent To Ib
Nov 27, 2022
Refusal Processed By Ib
Dec 1, 2022
Letter Of Protest Evidence Forwarded
Dec 22, 2022
Teas Response To Office Action Received
Dec 22, 2022
Correspondence Received In Law Office
Dec 22, 2022
Teas/Email Correspondence Entered
Jan 30, 2023
Non-Final Action Written
Jan 30, 2023
Non-Final Action E-Mailed
Jan 30, 2023
Notification Of Non-Final Action E-Mailed
Jun 7, 2023
Notification Of Possible Opposition Sent To Ib
Jun 7, 2023
Notification Of Possible Opposition Created, To Be Sent To Ib
Jul 26, 2023
Correspondence Received In Law Office
Jul 26, 2023
Teas/Email Correspondence Entered
Jun 26, 2023
Notification Of Possible Opposition - Processed By Ib
Jul 26, 2023
Teas Response To Office Action Received
May 2, 2024
Abandonment - Failure To Respond Or Late Response
May 2, 2024
Abandonment Notice E-Mailed - Failure To Respond
Oct 20, 2023
Notification Of Final Refusal Emailed
Oct 20, 2023
Final Refusal Written
Oct 20, 2023
Final Refusal E-Mailed
Trademark Alertz updated from USPTO on 2030-01-24
